International journal of biological macromolecules
Cure8 research brief
Why This Matters
The study suggests a new microbiota–metabolite–immune pathway (palmitic acid → PI3K/AKT → NETs) that may drive colitis and that Forsythia polysaccharides can modify, which could point to future microbiota-targeted therapies for IBD.
Who Should Pay Attention
Researchers; clinicians interested in IBD mechanisms and microbiome-targeted therapies; preclinical drug-discovery teams.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study (abstract) reports that polysaccharides from Forsythia (FPs) reduced inflammation and colonic injury in a mouse model of DSS-induced colitis.
The authors link the benefits to changes in the gut microbiota and metabolites — notably reduced palmitic acid (PA) — and to suppression of the PI3K/AKT signaling pathway and neutrophil extracellular trap (NET) formation.
They also report that giving PA partly reversed the protective effects and that pharmacologic PI3K/AKT inhibition countered PA-driven worsening. The work is preclinical and mechanistic: it uses a chemical colitis model (DSS), microbiome and metabolomic analyses, fecal microbiota transplantation, and pathway modulation to propose a PA–PI3K/AKT–NETs axis.
FPs are presented as a microbiota-targeted candidate that lowered PA and inflammation in this model. This is promising early-stage research but not clinical evidence. It does not establish safety or efficacy of Forsythia polysaccharides in people with IBD, and mouse-model pathways do not always translate to humans.
Keep In Mind
Findings are from a DSS-induced colitis model (preclinical) and are hypothesis-generating. Human relevance and safety of Forsythia polysaccharides are not established.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternational journal of biological macromolecules
AuthorsPeng Cheng, Ying Huang, Yixiang Luo +8 more
InstitutionDrum Tower Hospital Clinical College, Nanjing Drum Tower Hospital, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 4, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Callistephus A from Callistephus chinensis Alleviates DSS-Induced Ulcerative Colitis and Gut-liver Axis Disruption by Targeting the JAK2/STAT1 Pathway and Remodeling Gut Microbiota.
The study identifies a plant-derived compound that reduced inflammation and liver injury in a mouse model of ulcerative colitis and ties its effects to both JAK2/STAT1 inhibition and changes in the gut microbiota—two...
Poricoic acid a ameliorates ulcerative colitis via AMPK/PPARγ pathway-dependent cellular senescence inhibition and concomitant gut microbiota-metabolome modulation.
This study identifies a plant-derived compound (poricoic acid A) that reduced inflammation, cellular senescence, and colon injury in cell and mouse models of ulcerative colitis and links those effects to AMPK/PPARγ...
Lacticaseibacillus rhamnosus -Derived Extracellular Vesicles Alleviate Colitis via PPAR Signaling and the Gut Microbiota–Metabolite Axis
This preclinical study suggests probiotic-derived extracellular vesicles may reduce intestinal inflammation and restore barrier function via PPARγ signaling and changes to the gut microbiome—an early step toward...